About the project

Clinical trials against variants of COVID-19

What is RBDCOV

RBDCOV is a clinical trial that tests how efficient, tolerable, in terms of side-effects, and safe, the HIPRA’s vaccine against the different variants of COVID-19. The Covid-19 vaccine being developed by HIPRA is an adjuvanted recombinant protein vaccine, based on a receptor binding domain (RBD) fusion heterodimer containing variants B.1.1.7 (alpha) and B.1.351 (beta) of SARS-CoV-2.

As we all know, COVID-19 is a respiratory disease categorized by the WHO as a pandemic that has provoked obviously
a health crisis, but a socio-economic crisis too because of the measured needed and adopted by the different countries to try to contain the spread of the virus.

rbdcov vaccine researcher lab
13
Partners
0
Countries
2 M
Budget
20
Months

What RBDCOV
will do

The purpose behind RBDCOV project is to offer a new tool to control the pandemic at short-medium and long term, and to manufacture and test the first recombinant protein-based vaccine to be authorised in Europe.

RBDCOV is going to generate robust data to demonstrate the safety and immunogenicity of this vaccine given as a booster vaccination to induce higher and more durable immune response, specially towards new and future viral variants, which will be bridged for the effectiveness in the prevention of COVID-19.

The proposed strategy benefits from the partners experience in different fields and will permit to address the following issues that should permit a significant advancement:

  • Flexible platform ready to generate
    antigens of any future variants.
  • Inclusion of children and immunocompromised adults.
  • Booster for future vaccine campaigns.
  • Other challenges associated with COVID vaccination.
  • Understand the importance and limits of developing new vaccines in a pandemic situation.
rbdcov vaccine researcher lab